Sign In
Buy CCCC
$4.22
+0.1000 (+2.43%)
At Close: Jun 23, 2026
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022
07:00am, Wednesday, 06'th Jan 2021
– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial
C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach
05:00am, Sunday, 27'th Dec 2020
C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degrad
U.S. IPO Weekly Recap: IPO Launches And Filings Abound In The Post-Labor Day Frenzy
11:29am, Sunday, 13'th Sep 2020
One IPO and nine SPACs went public this past week. Thirteen IPOs and eleven SPACs submitted initial filings as the IPO market gears up for a busy September.
